Dow Up0.36% Nasdaq Up0.12%

Acasti Pharma Inc. (ACST)

0.97 Up 0.01(1.25%) Aug 21, 3:57PM EDT
ProfileGet Profile for:
Acasti Pharma Inc.
545 Promenade du Centropolis
Suite 100
Laval, QC H7T 0A3
Canada - Map
Phone: 450-686-4555
Fax: 450-686-2505

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Acasti Pharma Inc.

Key Executives 
Mr. Pierre Lemieux Ph.D., M.D.,
Chief Operating Officer
Dr. Fotini Sampalis M.D., Ph.D., 51
Chief Global Strategic Officer
Dr. Harlan W. Waksal M.D., 61
Exec. VP of Bus. & Scientific Affairs, Director and Member of Corp. Governance Committee
Mr. Andre Godin CPA, CA, 50
Interim Chief Exec. Officer, Interim Pres and Interim Chief Financial Officer
Mr. John Ripplinger ,
Director of Investor Relations
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders